Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Getinge’s Q2 “broadly in line”

This article was originally published in Clinica

Executive Summary

Swedish medtech firm Getinge may have problems reaching its full-year targets after a weak first half of 2012, according to Jefferies analyst Ingeborg Øie. She described the firm’s second fiscal quarter performance as “mixed”, but “broadly in-line”. The firm reported Q2 group sales of SEK5.61bn ($805.9m), up 13% (+0.4% on constant currency basis) and close to Jefferies estimate of SEK5.598bn, but 1% below consensus analyst expectations. Getinge has reiterated its outlook for full-year 2012, saying it expects to see organic sales growth higher than the 4.2% posted in 2011, as well as profit growth. But Ms Øie cautioned: “Our and consensus organic growth estimates of 4.1% and 4.2%, respectively, would put in question whether the full-year growth target can be reached after these weak results.”





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts